Update shared on 29 Nov 2025
Fair value Increased 0.85%Analysts have slightly raised their price target for NeoGenomics from $13.06 to $13.17 per share. This reflects updated assessments of future profitability and market growth potential.
What's in the News
- NeoGenomics will present research at the ISLB Annual Congress 2025 showing a 97% concordance between RaDaR ST and RaDaR 1.0 assays for detecting molecular residual disease in solid tumors (Key Developments).
- The company will highlight progress in its NextGen whole genome-based MRD research program and share validation findings for the NEO | PanTracer LBx assay, which support therapy selection and actionable biomarker identification in advanced cancers (Key Developments).
- NeoGenomics reaffirmed its 2025 full-year earnings guidance, projecting consolidated revenue between $720 million and $726 million, despite an expected increase in net loss compared to 2024 (Key Developments).
- At the ESMO Congress 2025, NeoGenomics will present new MRD assay data, illustrating how its RaDaR ST assay supports oncology drug development with high sensitivity and specificity for ctDNA detection (Key Developments).
Valuation Changes
- Fair Value Estimate has risen slightly from $13.06 to $13.17 per share.
- Discount Rate is virtually unchanged, moving marginally from 6.96% to 6.96%.
- Revenue Growth Projection has dipped modestly, from 9.88% to 9.81%.
- Net Profit Margin forecast has decreased fractionally from 5.48% to 5.47%.
- Future P/E Ratio estimate has increased from 40.87x to 41.40x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.